Overview: Autoimmune Interstitial Lung Disease Panel
Introduction: The Autoimmune Interstitial Lung Disease Panel is a diagnostic tool designed to screen for interstitial lung diseases with autoimmune etiology using serum samples. In India, connective tissue disease-associated ILD (e.g., scleroderma, myositis) is common, with prevalence 10-30 percent in rheumatology cohorts and high burden in women with Raynaud's or arthritis. Antibodies like anti-Jo-1, anti-Scl-70, anti-Ro-52 indicate progressive fibrosis. High morbidity from underdiagnosis in rural areas, limited HRCT/pulmonology access, overlap with TB/post-TB fibrosis, delayed immunosuppression leading to respiratory failure. Per pulmonology practices aligned with ICMR and Indian Chest Society guidelines, the test employs immunoassay for antibody detection over 1-2 days with high sensitivity/specificity, valuable for identifying autoimmune drivers in ILD. This diagnostic falls under autoimmune screening and targets patients with suspected CTD-ILD, addressing accurate detection to guide therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing fibrosis progression. Its serum-based approach ensures reliable detection.
Other Names: Auto ILD Pnl.
FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.
Historical Milestone: Expanded for CTD-ILD; in India, prominence with rising rheumatology-pulmonology overlap.
Purpose: The test screens for 8 parameters including anti-Jo-1 to guide ILD assessment, identify autoimmune triggers, inform immunosuppressive therapy.
Test Parameters: 1. Anti-Jo-1, 2. Anti-PL-7, 3. Anti-PL-12, 4. Anti-Mi-2, 5. Anti-Ku, 6. Anti-Scl-70, 7. Anti-Ro-52, 8. Anti-PM-Scl.
Pretest Condition: No fasting required; patients should report dyspnea, dry cough, joint pain, Raynaud's.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on dyspnea, cough, joint symptoms, family autoimmune history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated ILD including respiratory failure, benefits of early detection, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive antibodies indicate autoimmune ILD, necessitating specialist input. Negative may require follow-up if symptoms persist.
Specialist Consultation: Pulmonologists or rheumatologists should be consulted for management.
Additional Supporting Tests: HRCT chest, PFTs for confirmation.
Test Limitations: May miss rare antibodies; comprehensive approach required.
References: Indian Journal of Chest Diseases 2024, ILD Studies India 2023.
